Loading Events

« All Events

  • This event has passed.

FASEB-The Polycystic Kidney Disease Conference: Hurdles and Advances in Molecular Mechanisms and Therapies July 24-29, 2022 Lisbon, Portugal

July 24 - July 29

The Polycystic Kidney Disease Conference: Hurdles and Advances in Molecular Mechanisms and Therapies


Register Here


Launched in 2002, this FASEB Science Research Conference (SRC) focuses on the inherited renal cystic diseases including the autosomal dominant (ADPKD) and recessive (ARPKD) forms of polycystic kidney disease (PKD), the overlapping autosomal dominant polycystic liver diseases (ADPLD), and many syndromic forms of PKD, such as ciliopathies.

Identification of genes mutated in many of these disorders has improved the understanding of their pathophysiology, made the development of orthologous animal models possible, and facilitated the identification of therapeutic targets and the implementation of preclinical and clinical trials.

The conference focuses on recent advances in the pathogenic mechanisms underlying PKD and PKD-related disorders, and the development of therapies to slow their progression. It brings together basic scientists, clinical researchers and investigators, early-stage investigators, trainees, funding agencies, and medical science liaisons from pharmaceutical companies who will share and promote cross-disciplinary discussions and collaboration.

The participants’ wide range of disciplines include nephrology, gastroenterology, cell biology, genetics, physiology, biochemistry and structural biology, developmental biology, molecular medicine, pharmacology, and health sciences.

Important Dates

Abstract Deadline: June 13, 2022
Early Registration Deadline: June 23, 2022
Housing Deadline: June 24, 2022
Cancellation Deadline: July 3, 2022
Registration Closing Deadline: July 20, 2022

Keynote Lecture

Masayuki Yamamoto, PhD, Tohoku University


The conference’s main themes are: 1) PKD genetic, protein structures, biologic functions and interactions; 2) Molecular pathologies triggered in PKD: metabolism, inflammation, and fibrosis; 3) Discoveries on PKD cystogenic mechanisms: signaling, high-throughput screening and model systems such as organoids; 4) New therapeutic targets, biomarkers, and clinical trials. View the preliminary agenda.